$132 Million is the total value of Altium Capital Management LP's 68 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 380.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMGN | New | IMMUNOGEN INC | $9,151,950 | – | 485,000 | +100.0% | 6.93% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $8,778,000 | – | 228,000 | +100.0% | 6.64% | – |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $7,322,287 | +35.4% | 668,702 | +7.9% | 5.54% | +84.7% |
| HRMY | Buy | HARMONY BIOSCIENCES HLDGS IN | $5,274,594 | +438.5% | 149,889 | +399.6% | 3.99% | +633.8% |
| New | GRI BIO INC | $5,011,966 | – | 1,179,286 | +100.0% | 3.79% | – | |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $4,488,000 | – | 88,000 | +100.0% | 3.40% | – | |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $4,229,811 | +32.9% | 41,485 | +18.5% | 3.20% | +81.3% |
| New | JASPER THERAPEUTICS INC | $3,929,160 | – | 2,868,000 | +100.0% | 2.97% | – | |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $3,572,380 | – | 323,000 | +100.0% | 2.70% | – |
| New | BRIDGEBIO PHARMA INCput | $3,440,000 | – | 200,000 | +100.0% | 2.60% | – | |
| SRPT | New | SAREPTA THERAPEUTICS INC | $3,206,560 | – | 28,000 | +100.0% | 2.43% | – |
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $2,970,426 | – | 207,432 | +100.0% | 2.25% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $2,874,400 | – | 40,000 | +100.0% | 2.18% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $2,799,300 | – | 310,000 | +100.0% | 2.12% | – |
| COGT | New | COGENT BIOSCIENCES INC | $2,782,400 | – | 235,000 | +100.0% | 2.11% | – |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $2,432,700 | +51.5% | 135,000 | +35.0% | 1.84% | +106.6% |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $1,638,750 | – | 1,425,000 | +100.0% | 1.24% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $1,324,600 | -32.7% | 740,000 | +46.3% | 1.00% | -8.2% |
| KOD | New | KODIAK SCIENCES INC | $1,035,000 | – | 150,000 | +100.0% | 0.78% | – |
| IMVT | New | IMMUNOVANT INC | $665,847 | – | 35,100 | +100.0% | 0.50% | – |
| New | MARPAI INC | $201,520 | – | 117,848 | +100.0% | 0.15% | – | |
| New | FIBROGEN INCcall | $94,500 | – | 35,000 | +100.0% | 0.07% | – | |
| MBTCR | New | NOCTURNE ACQUISITION CORPright 12/26/2025 | $62,550 | – | 500,000 | +100.0% | 0.05% | – |
| New | FIBROGEN INCput | $45,900 | – | 17,000 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
| XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
| IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
| MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
| HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
| CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
| CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
| POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
| Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
| HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
| Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
| NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| 1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
| BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
| BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-08 |
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.